See more : East Morgan Holdings, Inc. (EMHI) Income Statement Analysis – Financial Results
Complete financial analysis of Zura Bio Limited (94E.F) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zura Bio Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Tecnosolo Engenharia S.A. (TCNO4.SA) Income Statement Analysis – Financial Results
- Heian Ceremony Service Co.,Ltd. (2344.T) Income Statement Analysis – Financial Results
- B-SOFT Co.,Ltd. (300451.SZ) Income Statement Analysis – Financial Results
- Newebinfo (6938.TWO) Income Statement Analysis – Financial Results
- Spenda Limited (SPX.AX) Income Statement Analysis – Financial Results
Zura Bio Limited (94E.F)
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.00M | 23.69M | 0.00 |
| General & Administrative | 0.00 | 2.68M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 18.64M | 2.68M | 1.09M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.64M | 2.68M | 1.09M |
| Cost & Expenses | 62.64M | 2.68M | 1.09M |
| Interest Income | 2.19M | 570.00 | 23.48K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K |
| EBITDA | -60.56M | -27.33M | 8.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.64M | -2.68M | -1.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.08M | -24.66M | 9.51M |
| Income Before Tax | -60.56M | 3.55M | 8.42M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -203.00K | -570.00 | -236.56K |
| Net Income | -60.36M | 3.55M | 8.42M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -2.09 | 0.21 | 0.40 |
| EPS Diluted | -2.09 | 0.21 | 0.40 |
| Weighted Avg Shares Out | 33.06M | 17.25M | 17.25M |
| Weighted Avg Shares Out (Dil) | 33.06M | 17.25M | 17.25M |
Source: https://incomestatements.info
Category: Stock Reports